Terumo Blood and Cell Technologies' IMUGARD Platelet Pooling Set Cleared by FDA
IMUGARD to Help Strained
Terumo Blood and Cell Technologies is a medical technology company that makes products that collect, process and separate blood and cells. Platelets are a component of human blood that form clots and stop bleeding. They are used to treat many different patients, such as those undergoing chemotherapy, organ transplants and bone marrow transplants. In 2021, more than 2.5 million units of platelets were transfused in the
Terumo Blood and Cell Technologies' latest innovation aims to increase the availability of platelets for transfusion. IMUGARD enables extended shelf life of platelets from the standard five days to seven days.[1] This can help blood centers better manage supply to meet patient needs and reduce waste.[2,3]
Most of the platelets in
"We continue to invest in innovations that help blood centers to positively impact patients," says
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in
[1] |
[2] Delage G, Bernier F, Beaudoin J, Thibault S, Dion J, Gagné L. Improved bacterial culture of platelet product: preliminary results after implementation of a two-bottle system with 48-hour sampling. Transfusion. 2016:56(S4);28A. |
[3] Harm SK, Szczepiorkowski ZM, Dunbar NM. Routine use of Day 6 and Day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation. Transfusion. 2018;58(4):938-942. |
IMUGARD® WB PLT Platelet Pooling Set
IMUGARD is the first platelet pooling set approved for seven-day storage in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-blood-and-cell-technologies-imugard-platelet-pooling-set-cleared-by-fda-301749297.html
SOURCE Terumo Blood and Cell Technologies